Pzena Investment Management LLC Acquires 88,094 Shares of Sanofi $SNY

Pzena Investment Management LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 348.2% during the third quarter, HoldingsChannel.com reports. The fund owned 113,396 shares of the company’s stock after purchasing an additional 88,094 shares during the quarter. Pzena Investment Management LLC’s holdings in Sanofi were worth $4,675,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of SNY. Provenance Wealth Advisors LLC grew its position in Sanofi by 359.8% during the 3rd quarter. Provenance Wealth Advisors LLC now owns 2,322 shares of the company’s stock worth $96,000 after purchasing an additional 1,817 shares during the last quarter. Gallacher Capital Management LLC increased its stake in Sanofi by 6.3% in the third quarter. Gallacher Capital Management LLC now owns 6,777 shares of the company’s stock valued at $279,000 after purchasing an additional 402 shares during the period. Signature Equity Partners LLC raised its holdings in shares of Sanofi by 322.2% in the third quarter. Signature Equity Partners LLC now owns 857 shares of the company’s stock valued at $35,000 after buying an additional 654 shares during the last quarter. Trek Financial LLC raised its holdings in shares of Sanofi by 11.3% in the third quarter. Trek Financial LLC now owns 6,852 shares of the company’s stock valued at $283,000 after buying an additional 696 shares during the last quarter. Finally, Walled Lake Planning & Wealth Management LLC purchased a new stake in shares of Sanofi in the third quarter valued at about $1,892,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SNY. HSBC reiterated a “buy” rating on shares of Sanofi in a research note on Thursday, September 10th. UBS Group restated a “neutral” rating on shares of Sanofi in a research report on Thursday, September 17th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a research note on Tuesday, September 29th. Berenberg Bank reaffirmed a “buy” rating on shares of Sanofi in a research note on Monday, October 5th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a research report on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $49.50.

Sanofi Stock Performance

NASDAQ:SNY opened at $46.91 on Friday. The firm’s fifty day moving average price is $42.25 and its 200 day moving average price is $44.33. Sanofi has a 1-year low of $39.07 and a 1-year high of $52.68. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.12 and a quick ratio of 0.64. The firm has a market cap of $113.73 billion, a price-to-earnings ratio of 23.22, a price-to-earnings-growth ratio of 1.30 and a beta of 0.31.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 30th. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.56 by $0.48. The company had revenue of $17.25 billion for the quarter, compared to analysts’ expectations of $14.30 billion. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. Sanofi’s revenue was up 16.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.91 EPS. On average, sell-side analysts expect that Sanofi will post 5.07 EPS for the current year.

Sanofi Company Profile

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.